

# Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBI-Sponsored WISE Study

Steven M. Smith, PharmD, MPH; Tianyao Huo, MS; B. Delia Johnson, PhD; Vera Bittner, MD, MSPH; Sheryl F. Kelsey, PhD; Diane Vido Thompson, MS; C. Noel Bairey Merz, MD; Carl J. Pepine, MD; Rhonda M. Cooper-DeHoff, PharmD, MS

**Background**—Women are more likely than men to develop resistant hypertension, which is associated with excess risk of major adverse outcomes; however, the impact of resistant hypertension in women with ischemia has not been explicitly studied. In this Women's Ischemia Syndrome Evaluation (WISE) analysis, we assessed long-term adverse outcomes associated with apparent treatment-resistant hypertension (aTRH) among women with suspected myocardial ischemia referred for coronary angiography.

**Methods and Results**—Women (n=927) were grouped according to baseline blood pressure (BP): normotensive (no hypertension history, BP <140/90 mm Hg, no antihypertensive drugs); controlled (BP <140/90 mm Hg and a hypertension diagnosis or on 1 to 3 drugs); uncontrolled (BP ≥140/90 mm Hg on ≤2 drugs); or aTRH (BP ≥140/90 mm Hg on 3 drugs or anyone on ≥4 drugs). Adverse outcomes (first occurrence of death [any cause], nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure or angina) were collected over 10 years of follow-up. Apparent treatment-resistant hypertension prevalence was 10.4% among those with hypertension. Women with aTRH had a greater incidence of adverse outcomes, compared with normotensive women (adjusted hazard ratio [HR], 3.25; 95% confidence interval [CI], 1.94 to 5.43), and women with controlled (HR, 1.77; 95% CI, 1.26 to 2.49) and uncontrolled (HR, 1.62; 95% CI, 1.15 to 2.27) hypertension; outcome differences were evident early in follow-up. Risk of all-cause death was greater in the aTRH group, compared to the normotensive women and women with controlled and uncontrolled hypertension.

**Conclusions**—In this cohort of women with evidence of ischemia, aTRH was associated with a profoundly increased long-term risk of major adverse events, including death, that emerged early during follow-up. (*J Am Heart Assoc.* 2014;3:e000660 doi: 10.1161/JAHA.113.000660)

**Key Words:** hypertension • resistant hypertension • WISE • women

Hypertension (HTN) affects an estimated 1 billion adults globally and is a major modifiable risk factor for ischemic heart disease, stroke, heart failure, diabetes, and death.<sup>1,2</sup> An estimated 8% to 12% or more of those with HTN

are believed to have resistant HTN,<sup>3</sup> usually defined as requiring ≥4 antihypertensive agents to achieve blood pressure (BP) control, and identified as a priority research area.<sup>4</sup> Previous studies have shown that resistant HTN, as compared with nonresistant HTN, is associated with an increased risk of major adverse cardiovascular (CV) events, all-cause mortality, or both, as well as lower health-related quality of life.<sup>5–9</sup> Furthermore, in a recent analysis, resistant HTN portended an increased risk of major adverse CV outcomes in patients with HTN and established coronary artery disease (CAD).<sup>10</sup> Yet, important questions remain, including whether the increased risk for adverse CV outcomes associated with resistant HTN is present in women specifically presenting for evaluation of symptoms and signs of ischemia and whether this risk remains over the long term.

Until recently, limited information was available regarding sex differences in HTN control and related outcomes. Overall prevalence of HTN appears to be similar among men and women, considering the entire age spectrum; however, more men than women have HTN at ages <45 years, whereas the

From the Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL (S.M.S., R.M.C.-D.); Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL (S.M.S.); Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL (T.H., C.J.P., R.M.C.-D.); Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (B.D.J., S.F.K.); Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL (V.B.); Allegheny General Hospital, Pittsburgh, PA (D.V.T.); Barbara Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Los Angeles, CA (C.N.B.M.).

**Correspondence to:** Steven M. Smith, PharmD, MPH, University of Florida, PO Box 100486, Gainesville, FL 32610. E-mail: ssmith@cop.ufl.edu

Received November 8, 2013; accepted January 9, 2014.

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

reverse is true in those  $\geq 65$ .<sup>1,11</sup> Women are more likely to be treated with antihypertensive drugs and prescribed a greater number of antihypertensive drugs, yet less likely to achieve BP control than age-matched men, particularly in aging populations.<sup>11–18</sup> Accordingly, several studies indicate that resistant HTN populations have a greater ratio of females to males than do nonresistant HTN populations and that female sex is an independent predictor of resistant HTN.<sup>7,10,18,19</sup> On the other hand, women with HTN in general have a lower risk for mortality and most adverse CV outcomes, compared to age-matched men with HTN.<sup>20–22</sup> This appears true even in older populations, where HTN is more prevalent and poorly controlled in women,<sup>23</sup> despite similar protection afforded both by antihypertensive therapies.<sup>24</sup> Thus, it would appear that women are less likely than men to experience adverse CV events, but more likely to develop resistant HTN. Whether resistant HTN portends increased risk of adverse outcomes in women has not been explicitly studied and risks associated with ischemia are unknown.

Therefore, the aim of this study was to ascertain the long-term risk of adverse outcomes associated with apparent treatment-resistant HTN (aTRH) in women with signs and symptoms of cardiac ischemia. We hypothesized that aTRH would be associated with an increased risk for adverse CV outcomes. To test this hypothesis, we analyzed data from the Women's Ischemia Syndrome Evaluation (WISE).

## Methods

### Study Design

The WISE study design and protocol details have been previously published.<sup>25</sup> Briefly, WISE is a National Heart, Lung and Blood Institute–sponsored observational cohort study aimed at improving recognition, diagnosis, and understanding of pathophysiologic mechanisms underlying ischemic heart disease in women. Women undergoing clinically indicated coronary angiography for symptoms and/or signs of ischemia were enrolled from September 1996 through March 2000 from four academic institutions, including the University of Alabama–Birmingham, University of Pittsburgh, University of Florida, and Allegheny General Hospital. Major exclusion criteria included comorbidities that compromised follow-up, pregnancy, contraindications to provocative diagnostic testing, cardiomyopathy, New York Heart Association class III to IV heart failure, recent myocardial infarction (MI), significant valvular or congenital heart disease, and language barrier to questionnaire testing. Each woman gave informed consent before enrollment. All clinical centers had institutional review board approval for inclusion of women in this cohort study as well as for collection of follow-up data.

### Baseline and Follow-up Procedures

Baseline evaluations included collection of demographics, medical history, symptom data, physical examination and blood sampling for lipids, reproductive hormones, and inflammatory markers, as described in detail elsewhere.<sup>25</sup> Blood pressure was measured in the clinic/office setting at centers very experienced in the treatment of HTN care and following routine clinical standards in line with what was outlined by JNC 6,<sup>26</sup> which was current during collection of the BP data described in this manuscript. Blood pressure was measured with women seated and after having rested for at least 5 minutes. Blood pressure values represented either antihypertensive-naïve or on-treatment BP if a baseline antihypertensive regimen was prescribed by a participant's primary physician. Coronary angiography analyses were performed by a core lab masked to all patient data, including symptoms and results of noninvasive testing. Any diameter stenosis  $\geq 50\%$  was considered obstructive CAD.<sup>27</sup> Outcome data used here were collected in two consecutive phases, as described previously.<sup>28</sup> During phase I (median duration, 6 years), women were contacted at 6 weeks and at 1-year intervals following enrollment. During telephone contact, a scripted interview was completed by an experienced nurse or physician at the respective center: Each patient (or a family member, for women who died or were lost to follow-up) was queried for occurrence of major adverse cardiac events or hospitalizations. For cases cared for at a WISE clinical center, patients' medical records were also reviewed. In the event of death, a death certificate and/or physician narrative was obtained. During the second phase, we conducted a National Death Index search to 10 years of median follow-up for those who were alive at last contact and had not withdrawn consent. All deaths were adjudicated as CV or non-CV by a committee of senior WISE investigators blinded to angiographic findings.

### Definition of HTN Groups and Assembly of Study Cohort

For this analysis, women were assigned to one of four groups according to baseline BP and antihypertensive use as follows: (1) normotensive, defined as no self-reported history of HTN, BP  $< 140/90$  mm Hg, and taking no antihypertensive drugs; (2) controlled HTN, defined as BP  $< 140/90$  mm Hg and either a self-reported previous HTN diagnosis (if taking no antihypertensive drugs) or use of 1 to 3 antihypertensive drugs irrespective of HTN diagnosis; (3) uncontrolled HTN, defined as BP  $\geq 140/90$  mm Hg using  $\leq 2$  antihypertensive drugs; and (4) aTRH, defined as BP  $\geq 140/90$  on  $\geq 3$  antihypertensive drugs or BP  $< 140/90$  mm Hg using  $\geq 4$  antihypertensive drugs. The normotensive group was the reference in all analyses.

## Outcomes

The primary outcome for this analysis was the first occurrence of death from any cause (including phase II data), nonfatal MI, nonfatal stroke, or hospitalization for heart failure or angina. All-cause death (including extended follow-up from phase II) was a secondary outcome.

## Statistical Analyses

Demographics and major events were summarized using mean±SD for continuous variables and n (%) for categorical variables. Comparisons across the four study groups were made using Fisher's exact test for categorical variables and Kruskal-Wallis' test for continuous variables. The log-rank test was used to test overall differences in outcomes among groups. Cox's regression models were fit to adjust covariates that were significantly different between groups. Candidate variables for the full models included age, race (nonwhite), history of diabetes, history of dyslipidemia, presence of obesity (defined as body mass index [BMI] >30 kg/m<sup>2</sup>), history of smoking, presence of obstructive CAD, and family history of CAD. Models were developed using backward selection with age forced into the model; otherwise, only covariates with a *P* value <0.10 remained in the final model. The proportional hazard assumption was checked by creating and adding time-dependent covariates in the model; no significant violation of the assumption was detected. A hazard ratio (HR) and 95% confidence intervals (CIs) were estimated for each variable. Unadjusted Kaplan-Meier survival curves were plotted for each outcome. Overall *P* values ≤0.05 were considered significant. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).

## Results

A total of 927 women with available BP, angiographic, and follow-up outcomes data were included in this analysis. At baseline, only 131 (14.1%) of these women were normotensive. Among the remaining 796 women with HTN, 390 (48.9%) had controlled HTN (BP <140/90 mm Hg), 323 (40.6%) had uncontrolled HTN, and 83 (10.4%) had aTRH according to our definitions. Pertinent baseline characteristics for the entire study cohort and the individual groups are summarized in Table 1. Women with HTN, as compared with normotensive women, were older, on average, and had a higher baseline prevalence of diabetes, dyslipidemia, obesity, and obstructive CAD. Notably, women with aTRH had the highest prevalence of each of these comorbidities. Additionally, almost half of the women with aTRH were nonwhite, whereas fewer than 1 in 5 of women in the normotensive, controlled HTN, and uncontrolled HTN groups were nonwhite.

## Baseline BP and Medication Use

Mean±SD baseline systolic BP was similar for the normotensive and controlled HTN groups (120±12 vs. 123±12 mm Hg, respectively) and for the uncontrolled HTN and aTRH groups (154±15 vs. 158±21 mm Hg, respectively). Corresponding mean±SD baseline diastolic BPs were 73±8 and 72±9 mm Hg for the normotensive and controlled HTN groups and 83±10 and 81±13 mm Hg for the uncontrolled and aTRH groups.

Self-reported antihypertensive medication use at baseline is summarized in Table 1. By definition, use of ≥1 agent from each antihypertensive class was considerably more common in women with aTRH than in those with controlled or uncontrolled HTN. In those with aTRH at baseline, diuretics were the most commonly used agents (89% of women), followed by β-blockers (77%) and angiotensin converting enzyme (ACE) inhibitors (70%). In both the controlled and uncontrolled HTN groups, β-blockers were the most commonly used agent (50% and 33% of women in each group, respectively). Diuretics were used by 28% of those with controlled HTN and 25% of those with uncontrolled HTN. No women used aldosterone antagonists.

## Adverse CV and Mortality Outcomes

Adverse CV and mortality outcome event frequencies are summarized in Table 2. Unexpectedly, nearly half of the 796 women with HTN had at least one of the following events: death from any cause, nonfatal MI, nonfatal stroke, or hospitalization for heart failure or angina. In the aTRH group, 69% experienced an event, compared with 46% in the uncontrolled HTN group and 44% in the controlled HTN group. Considerably fewer women in the normotensive group experienced an event (21%), relative to the HTN groups (overall log-rank, *P*<0.0001). These differences in adverse outcome frequency between groups were evident very early in follow-up (Figure 1).

In multivariable-adjusted analyses controlling for age, race, and available clinical characteristics, HTN of any type was associated with a higher risk of adverse outcome, relative to normotensive women. Specifically, we observed a graded association whereby excess risk (relative to normotensive women) was intermediate in those with controlled HTN (HR, 1.84; 95% CI, 1.19 to 2.84) and uncontrolled HTN (HR, 2.01; 95% CI, 1.29 to 3.13) and highest in the aTRH group (HR, 3.25; 95% CI, 1.94 to 5.43). Women with aTRH also had greater risk, compared with those in the controlled (HR, 1.77; 95% CI, 1.26 to 2.49; *P*=0.001) and uncontrolled HTN (HR, 1.62; 95% CI, 1.15 to 2.27; *P*=0.006) groups. No difference was observed in risk between controlled and uncontrolled HTN groups (HR, 0.91; 95% CI, 0.72 to 1.16; *P*=0.45).

**Table 1.** Baseline Characteristics According to Study Group and for the Cohort

Variable	Overall (n=927)	Normotensive (n=131)	Controlled HTN (n=390)	Uncontrolled HTN (n=323)	Apparent Resistant HTN (n=83)	P Value*
Age, mean±SD	58±12	52±11	57±12	61±11	63±11	<0.0001
Nonwhite, %	19	12	15	19	46	<0.0001
HTN <sup>†</sup> , %	59	0	61	72	97	<0.0001
Diabetes, %	25	4	25	26	54	<0.0001
Dyslipidemia, %	51	30	60	53	77	<0.0001
Obese, %	40	31	39	44	48	0.019
Obstructive CAD, %	38	18	43	36	53	<0.0001
Family Hx of CAD, %	64	63	70	64	63	0.17
Hx of smoking, %	53	51	58	50	45	0.044
SBP (mm Hg), mean±SD	137±21	120±12	123±12	154±15	158±21	<0.0001
DBP (mm Hg), mean±SD	77±11	73±8	72±9	83±10	81±13	<0.0001
Antihypertensive drugs						
ACE inhibitor, %	26	0	29	22	70	—
ARB, %	3	0	2	3	13	—
β-blocker, %	39	0	50	33	77	—
Diuretic, %	29	0	28	25	89	—
Vasodilator, %	9	0	7	9	28	—
CCB, %	28	0	33	25	61	—
Number of antihypertensive drugs						
0 drugs, %	23	100	4	21	0	—
1 drug, %	39	0	56	43	0	—
2 drugs, %	25	0	28	37	0	—
≥3 drugs, %	14	0	12	0	100	—

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; DBP, diastolic blood pressure; HTN, hypertension; Hx, history; SBP, systolic blood pressure.

\*P values represent comparison across the four study groups using Fisher's exact test for categorical variables and Kruskal-Wallis' test for continuous variables. No group comparisons were made for antihypertensive drugs and number of antihypertensive drugs because these variables were either 0% or 100% for normotensive patients by definition.

<sup>†</sup>Self-reported diagnosis of hypertension at baseline.


**Table 2.** Outcome Frequency by Study Group

Outcome	Normotensive (n=131)	Controlled HTN (n=390)	Uncontrolled HTN (n=323)	Apparent Resistant HTN (n=83)	Total (n=927)
Primary outcome*, n (%)	28 (21)	170 (44)	149 (46)	57 (69)	404 (44)
Individual components of primary outcome					
Nonfatal MI, n (%)	1 (1)	15 (4)	12 (4)	5 (6)	33 (4)
Nonfatal Stroke, n (%)	4 (3)	17 (4)	15 (5)	6 (7)	42 (5)
HF hospitalization, n (%)	1 (1)	16 (4)	28 (9)	17 (20)	62 (7)
Angina hospitalization, n (%)	21 (16)	106 (27)	91 (28)	38 (46)	256 (28)
All-cause death, n (%)	5 (4)	81 (21)	63 (20)	34 (41)	183 (20)

HF indicates heart failure; HTN, hypertension; MI, myocardial infarction.

\*First occurrence of death from any cause (including extended follow-up), nonfatal MI, nonfatal stroke, or hospitalization for heart failure or angina.





**Figure 1.** Kaplan-Meier curve for primary outcome event-free survival according to hypertension group. HTN indicates hypertension.

**Table 3.** Independent Predictors From Multivariate Cox Regression Model for First Occurrence of Death From Any Cause (Including Phase II Data), Nonfatal MI, Nonfatal Stroke, or Hospitalization for Heart Failure or Angina

Parameter	HR (95% CI)	P Value
Age (per year)	1.00 (0.99 to 1.01)	0.45
Non-white	1.50 (1.15 to 1.95)	0.003
History of dyslipidemia (yes vs no)	1.30 (1.04 to 1.63)	0.021
Obstructive CAD (yes vs no)	1.93 (1.54 to 2.42)	<0.0001
History of smoking (yes vs no)	1.23 (0.99 to 1.52)	0.06
Normotensive (reference)	—	—
Controlled HTN	1.84 (1.19 to 2.84)	0.006
Uncontrolled HTN	2.01 (1.29 to 3.13)	0.002
Apparent resistant HTN	3.25 (1.94 to 5.43)	<0.0001

CAD indicates coronary artery disease; CI, confidence interval; HR, hazard ratio; HTN, hypertension; MI, myocardial infarction.

In addition to HTN type, the presence of obstructive CAD, nonwhite race, and history of dyslipidemia also contributed significantly to higher risk of adverse outcome (Table 3).


Among those with HTN, nearly 1 in 4 women died during the 10-year mortality follow-up period (Table 2). The proportion of women dying from any cause was highest in the aTRH group (41%), whereas death occurred less frequently in the uncontrolled HTN (20%) and controlled HTN (21%) groups. Only 4% of women in the normotensive group died. The Kaplan-Meier curve for the unadjusted analysis of all-cause death is displayed in Figure 2. After adjustment, HTN of any type was associated with an increased risk of all-cause death. The greatest excess risk, relative to normotensive women,

was observed in those with aTRH at baseline (HR, 7.36; 95% CI, 2.16 to 25.1), followed by those with controlled HTN (HR, 4.24; 95% CI, 1.31 to 13.7) and uncontrolled HTN (HR, 3.83; 95% CI, 1.17 to 12.5). Risk of all-cause death was also greater in women with aTRH, compared with controlled HTN (HR, 1.74; 95% CI, 1.07 to 2.81;  $P=0.03$ ) and uncontrolled HTN (HR, 1.92; 95% CI, 1.17 to 3.15;  $P=0.01$ ), whereas no difference in risk was observed between women with controlled versus uncontrolled HTN (HR, 1.11; 95% CI, 0.75 to 1.64;  $P=0.62$ ). Hazard ratios from the full Cox regression model for all-cause death are summarized in Table 4.

## Discussion

Despite increasing awareness of CVD as the leading cause of mortality for women, relatively few studies have focused on women in relation to CVD and associated outcomes.<sup>29</sup> We tested the hypothesis that aTRH, defined in this study as baseline BP  $\geq 140/90$  mm Hg using  $\geq 3$  antihypertensive drugs or use of  $\geq 4$  antihypertensive drugs regardless of BP, portends an increased risk of adverse outcomes among adult women with signs or symptoms of myocardial ischemia. We show, for the first time, that women, referred to coronary angiography to evaluate symptoms/signs of ischemia, with aTRH have a profoundly increased risk of CV events and all-cause mortality, compared with normotensive women and those without aTRH. Moreover, we observed an association with both first occurrence of nonfatal stroke, nonfatal MI, hospitalization for angina or heart failure, or all-cause death, and all-cause death alone, whereby women with aTRH consistently had the greatest excess risk, followed by those with nonresistant HTN (regardless of BP control), whereas normotensive individuals had the lowest risk. Importantly, this pronounced increase in risk occurred early in follow-up, particularly for the primary outcome, and persisted over the long term for both the primary outcome and all-cause mortality.

The substantial and early excess risk of adverse outcomes among women with aTRH enrolled in WISE is noteworthy for several reasons. First, this is the only study, to our knowledge, that has quantified risk associated with aTRH in a female-only population. Compared to men, women are known to have more difficulty achieving BP control, thus requiring more aggressive therapy, and, consequently, are more likely to develop resistant HTN. Recent data also indicate that women with HTN have a significantly lower risk of most major adverse CV events, CV mortality, and all-cause mortality, when compared to age-matched men with HTN.<sup>20–23</sup> However, resistant HTN in women has not been explicitly studied previously and whether or not aTRH portends increased risk in women has not been clearly established. Thus, our findings highlight two key points regarding aTRH in women: (1) Regardless of any sex difference in CV or mortality risk in the



**Figure 2.** Kaplan-Meier curve for survival from all-cause death according to hypertension group. HTN indicates hypertension.

**Table 4.** Independent Predictors From Multivariate Cox Regression Model for All-Cause Death

Parameter	HR (95% CI)	P Value
Age (per year)	1.03 (1.02 to 1.05)	0.0003
History of diabetes (yes vs no)	1.88 (1.31 to 2.72)	0.0007
History of smoking (yes vs no)	1.85 (1.29 to 2.65)	0.0009
Obstructive CAD (yes vs no)	1.83 (1.25 to 2.68)	0.002
Normotensive (reference)	—	—
Controlled HTN	4.24 (1.31 to 13.7)	0.017
Uncontrolled HTN	3.83 (1.17 to 12.5)	0.026
Apparent resistant HTN	7.36 (2.16 to 25.1)	0.001

CAD indicates coronary artery disease; HTN, hypertension.

overall hypertensive population, aTRH is associated with a profound increase in risk of adverse CV outcomes and death in women with symptoms/signs of ischemia, and (2) the association between aTRH and increased risk is independent of several traditional risk factors for adverse outcomes, including obstructive CAD, diabetes, dyslipidemia, and obesity. Second, the excess mortality risk associated with aTRH in the present study appears to persist for at least 10 years. To our knowledge, this is among the longest follow-up period reported in studies of resistant HTN. Most previous studies have included outcome assessment only up to 5 years.<sup>6–8,10</sup> Third, this substantial and long-term divergence in risk among the study groups was observed using only baseline clinic BP data. Almost assuredly, some of the women enrolled in WISE had pseudoresistant HTN, whereby baseline clinic BP (used in our definition of aTRH) was elevated, but 24-hour ambulatory BP would have been normal, had it been measured. Data from

the Spanish Ambulatory Blood Pressure Monitoring (ABPM) registry suggest that as many as  $\approx 40\%$  of women with aTRH based on clinic BP would not be classified as having resistant HTN on the basis of 24-hour ABPM (ie, pseudoresistant HTN).<sup>30</sup> Unfortunately, precise estimates of pseudoresistant HTN prevalence in this population are unavailable and 24-hour ABPM was not performed in the WISE. Nevertheless, persons with isolated clinic BP elevations (aka a “white coat” effect) have a lower risk than those with elevated clinic and 24-hour ambulatory BP in unselected HTN populations<sup>31,32</sup> and, possibly, resistant HTN populations.<sup>8</sup> Thus, the excess risk attributable to aTRH in the present study is all the more impressive because, presumably, a significant proportion of these women likely had only isolated clinic BP elevations at baseline.

Few studies have examined predictors of adverse outcomes in patients with aTRH. Age, smoking, low-density lipoprotein cholesterol, left ventricular hypertrophy, and diabetes have been suggested as predictors for adverse outcomes (eg, MI, stroke, renal failure requiring dialysis, coronary or peripheral revascularization, or heart failure hospitalization).<sup>5</sup> Among patients with chronic kidney disease, predictors of adverse outcome (ie, CV death or nonfatal CV event requiring hospitalization) included only increasing age, male sex, decreasing glomerular filtration rate, history of CV events, and “true” resistant HTN (ie, as assessed by 24-hour ambulatory BP); BMI and diabetes were not significantly associated with the adverse outcome and race was not considered in the model because only whites were enrolled.<sup>8</sup> Although not directly comparable in terms of CV outcomes or patient populations assessed, we found that, in addition to aTRH, independent predictors of adverse outcomes in women in our study included nonwhite race, history of dyslipidemia, and obstructive CAD. We found no evidence of obesity or diabetes being independently associated with the adverse outcome. However, diabetes was independently associated with all-cause death, as were age, obstructive CAD, and smoking. The apparent differences, between predictors of adverse events in these studies, likely reflect differences in patient populations, as well as definitions of outcomes and resistant HTN. Nevertheless, these data, taken together, clearly demonstrate that the association between adverse outcomes and aTRH is not simply a reflection of the known risk of comorbidities (eg, obstructive CAD) found more often in those with resistant HTN. Rather, resistant HTN likely reflects a sicker patient population with underlying pathophysiologic changes, for example, increased arterial stiffness<sup>33–35</sup> and/or sympathetic nervous system activation resulting in altered vascular repair interacting to aggravate myocardial ischemia.<sup>36–38</sup>

A final point is that although women enrolled in WISE had a higher prevalence of HTN than the general female adult

population, the 10.4% prevalence of aTRH among only those with HTN is generally consistent with previous analyses of resistant HTN prevalence in unselected patients with HTN.<sup>3</sup> Furthermore, this prevalence is similar to that observed in the Reduction of Atherothrombosis for Continued Health registry, where 12.7% of adults  $\geq 45$  years of age with  $\geq 3$  atherosclerotic risk factors or established disease had resistant HTN based on baseline BP data and antihypertensive drug use.<sup>7</sup> However, not surprisingly, we observed a considerably lower prevalence in the present study, compared with International VErampil SR-Trandolapril Study (INVEST) participants, who all had HTN and established CAD at baseline, where approximately one third had resistant HTN.<sup>10</sup>

Our study has some noteworthy limitations. First, BP and antihypertensive use data were collected only at baseline and thus our study groups were defined accordingly. We cannot exclude the possibility that some women would have been classified differently based on data from later time points (eg, just before an event). However, in analyses of INVEST data, outcomes did not differ among those with controlled resistant HTN versus uncontrolled resistant HTN.<sup>10</sup> Thus, it is unclear whether achievement of BP control, or lack thereof, would substantially alter outcomes in the aTRH group. Unfortunately, the group sizes and outcome frequency were too small to adequately compare women with controlled aTRH versus uncontrolled aTRH in the present study. Second, medication adherence and secondary causes of HTN were not examined in WISE participants. Some of these women likely were nonadherent to antihypertensive therapy and we cannot exclude the possibility that nonadherence may have impacted adverse event rates in the hypertensive groups, especially those with aTRH. Third, our findings are applicable to women with signs or symptoms of myocardial ischemia of sufficient severity to prompt referral for angiography and should not be extrapolated to all adult women. Specifically, patients referred to the WISE study had signs and symptoms of ischemia based on a variety of different positive diagnostic tests; whether our findings would apply to a cohort of women without ischemia referral bias is not clear. Fourth, without a comparative male cohort, it is unknown whether our findings would apply to men. Unlike our women, more men undergoing angiography are identified with obstructive CAD<sup>39,40</sup> and therefore more intensely targeted for therapy to prevent atherosclerosis progression. Future investigation should be directed at testing these concepts in men. WISE centers may also have observed a higher percentage of women referred for coronary angiography without obstructive CAD as a result of tertiary care referral bias and publicized interest in heart disease among women. Fifth, although we controlled for baseline presence of several known risk factors for major adverse CV events, we cannot exclude the possibility that unmeasured confounders impacted our results. Moreover, our findings should not be

construed as definitive proof of a causal relationship between aTRH and major adverse events. Sixth, nonfatal and fatal outcomes were verified by review of the medical records in all cases where records were available; however, we cannot exclude the possibility that some uncorroborated, patient-reported nonfatal outcomes may have been subject to misclassification. Finally, the WISE cohort had moderate rates of aspirin and statin medication use, both of which are known to reduce adverse outcomes in the absence of HTN. Use of these agents would have the potential to reduce risks and minimize relationships between the HTN groups and adverse outcomes and therefore lead to an underestimation of the observed relationships. Likewise,  $\beta$ -blocker and ACE inhibitor use were both greater in the aTRH group versus the nonresistant HTN groups, which would have the potential to result in underestimation of the relationship between aTRH and adverse outcomes in these women with evidence of myocardial ischemia.

In conclusion, this analysis confirms that aTRH is associated with a profound, early increase in risk of adverse outcomes among women with signs and symptoms of myocardial ischemia regardless of the presence of obstructive CAD. Furthermore, the risk of all-cause mortality associated with aTRH persists for at least 10 years from initial determination of resistant status. These findings fill a gap in the literature and have important implications for clinical practice and future research. Our observations reinforce the importance of recognizing women with, or at risk of developing, resistant HTN. Additionally, our findings highlight the need for future studies to clarify the pathophysiologic causes underlying increased CV risk in patients with aTRH and to determine appropriate risk reduction strategies, including pharmacologic and nonpharmacologic therapies.

## Sources of Funding

This work was supported by contracts from the National Heart, Lung and Blood Institutes (nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, and N01-HV-68164); grants U0164829, U01 HL649141, U01 HL649241, T32HL69751, R01 HL090957, and 1R03AG032631 from the National Institute on Aging; GCRC grant MO1-RR00425 from the National Center for Research Resources; the National Center for Advancing Translational Sciences (grant UL1TR000124); and grants from the Gustavus and Louis Pfeiffer Research Foundation, Danville, NJ; The Women's Guild of Cedars-Sinai Medical Center, Los Angeles, CA; The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA; and QMED, Inc., Laurence Harbor, NJ; the Edythe L. Broad Women's Heart Research Fellowship; Cedars-Sinai Medical Center, Los Angeles, CA; the Barbra Streisand Women's Cardiovascular



Research and Education Program; and The Society for Women's Health Research (SWHR), Washington, DC.

## Disclosures

None.

## References

- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005;365:217–223.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabwejian J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock K, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstein MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2095–2128.
- Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension—its identification and epidemiology. *Nat Rev Nephrol*. 2013;9:51–58.
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension*. 2008;51:1403–1419.
- Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, Caldarella MP, Neri M, Cuccurullo F, Mezzetti A. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. *Am J Hypertens*. 2005;18:1422–1428.
- Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation*. 2012;125:1635–1642.
- Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL; REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherosclerosis. *Eur Heart J*. 2013;34:1204–1214.
- De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G, Minutolo R. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. *J Am Coll Cardiol*. 2013;61:2461–2467.
- Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. *Hypertension*. 2012;60:1479–1484.
- Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-DeHoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. *J Hypertens*. 2014;32:635–643.
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. *Circulation*. 2013;127:e6–e245.
- McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. *J Gerontol A Biol Sci Med Sci*. 2009;64:256–263.
- Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999–2004. *Am J Hypertens*. 2008;21:789–798.
- Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. *Circulation*. 2012;126:2105–2114.
- Daugherty SL, Masoudi FA, Ellis JL, Ho PM, Schmittlieb JA, Tavel HM, Selby JV, O'Connor PJ, Margolis KL, Magid DJ. Age-dependent gender differences in hypertension management. *J Hypertens*. 2011;29:1005–1011.
- Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. *Hypertension*. 2008;51:1149–1155.
- Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. *JAMA*. 2005;294:466–472.
- Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, Facchetti R, Redon J, Mancia G, Grassi G. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. *J Hypertens*. 2013;31:2018–2024.
- Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *J Clin Hypertens (Greenwich)*. 2002;4:393–404.
- Daugherty SL, Masoudi FA, Zeng C, Ho PM, Margolis KL, O'Connor PJ, Go AS, Magid DJ. Sex differences in cardiovascular outcomes in patients with incident hypertension. *J Hypertens*. 2013;31:271–277.
- Quan H, Chen G, Walker RL, Wielgosz A, Dai S, Tu K, Campbell NR, Hemmelgarn BR, Hill MD, Johansen H, McAlister FA, Khan N. Incidence, cardiovascular complications and mortality of hypertension by sex and ethnicity. *Heart*. 2013;99:715–721.
- Quan H, Chen G, Tu K, Bartlett G, Butt DA, Campbell NR, Hemmelgarn BR, Hill MD, Johansen H, Khan N, Lix LM, Smith M, Svenson L, Walker RL, Wielgosz A, McAlister FA. Outcomes among 3.5 million newly diagnosed hypertensive Canadians. *Can J Cardiol*. 2013;29:592–597.
- Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT Jr. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. *Hypertension*. 2013;61:977–986.
- Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. *Eur Heart J*. 2008;29:2669–2680.
- Merz CN, Kelsey SF, Pepine CJ, Reichek N, Reis SE, Rogers WJ, Sharaf BL, Sopko G. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. *J Am Coll Cardiol*. 1999;33:1453–1461.
- JNC 6. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med*. 1997;157:2413–2446.
- Sharaf BL, Pepine CJ, Kerensky RA, Reis SE, Reichek N, Rogers WJ, Sopko G, Kelsey SF, Holubkov R, Olson M, Miele NJ, Williams DO, Merz CN. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–941; a3.
- Sharaf B, Wood T, Shaw L, Johnson BD, Kelsey S, Anderson RD, Pepine CJ, Bairey Merz CN. Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. *Am Heart J*. 2013;166:134–141.



29. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Pina IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. *Circulation*. 2011;123:1243–1262.
30. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. *Hypertension*. 2011;57:898–902.
31. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. *Hypertension*. 2013;62:168–174.
32. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. *Nat Rev Cardiol*. 2011;8:686–693.
33. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H Jr. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. *J Hum Hypertens*. 2011;25:532–538.
34. Muxfeldt ES, Cardoso CR, Dias VB, Nascimento AC, Salles GF. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension. *J Hypertens*. 2010;28:1547–1553.
35. Pabuccu T, Baris N, Ozpelit E, Akdeniz B, Guneri S. The relationship between resistant hypertension and arterial stiffness. *Clin Exp Hypertens*. 2012;34:57–62.
36. Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, Stefanadis C. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. *Int J Hypertens*. 2011;2011:642416.
37. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell*. 2006;124:407–421.
38. Dutta P, Courties G, Wei Y, Leuschner F, Gorbato R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T, Majmudar MD, Lasitschka F, Eitzrodt M, Waterman P, Waring MT, Chicoine AT, van der Laan AM, Niessen HW, Piek JJ, Rubin BB, Butany J, Stone JR, Katus HA, Murphy SA, Morrow DA, Sabatine MS, Vinegoni C, Moskowitz MA, Pittet MJ, Libby P, Lin CP, Swirski FK, Weissleder R, Nahrendorf M. Myocardial infarction accelerates atherosclerosis. *Nature*. 2012;487:325–329.
39. Smilowitz NR, Sampson BA, Abrecht CR, Siegfried JS, Hochman JS, Reynolds HR. Women have less severe and extensive coronary atherosclerosis in fatal cases of ischemic heart disease: an autopsy study. *Am Heart J*. 2011;161:681–688.
40. Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, Douglas PS, Krone RJ, McKay CR, Block PC, Hewitt K, Weintraub WS, Peterson ED. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. *Circulation*. 2008;117:1787–1801.